Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009)
An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)
Sponsor: Azevan Pharmaceuticals
Listed as NCT02055638, this PHASE1/PHASE2 trial focuses on Intermittent Explosive Disorder and remains completed. Sponsored by Azevan Pharmaceuticals, it has been updated 10 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2023 — Aug 2023 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Azevan Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .